These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 13678791)

  • 1. Pharmaceutical industry's barriers and preferences to conduct clinical drug trials in Finland: a qualitative study.
    Keinonen T; Keränen T; Klaukka T; Saano V; Ylitalo P; Enlund H
    Eur J Pharm Sci; 2003 Sep; 20(1):35-42. PubMed ID: 13678791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigator barriers and preferences to conduct clinical drug trials in Finland: a qualitative study.
    Keinonen T; Keränen T; Klaukka T; Saano V; Ylitalo P; Enlund H
    Pharm World Sci; 2003 Dec; 25(6):251-9. PubMed ID: 14689812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WHO guidelines for good clinical practice (GCP) for trials on pharmaceutical products: responsibilities of the investigator.
    Idänpään-Heikkilä JE
    Ann Med; 1994 Apr; 26(2):89-94. PubMed ID: 8024733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of clinical trials by Ethics Committees in Germany--results and a comparison of two surveys performed among members of the German Association of Research-Based Pharmaceutical Companies (vfa).
    Russ H; Busta S; Jost B; Bethke TD
    Ger Med Sci; 2015; 13():Doc02. PubMed ID: 25698912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experiences with GCP in the pharmaceutical industry [corrected].
    Rämsch KD
    Methods Find Exp Clin Pharmacol; 1993 May; 15(4):237-40. PubMed ID: 8240533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Success and failure factors of patient recruitment for industry-sponsored clinical trials and the role of the electronic health records-a qualitative interview study in the Nordic countries.
    Laaksonen N; Bengtström M; Axelin A; Blomster J; Scheinin M; Huupponen R
    Trials; 2022 May; 23(1):385. PubMed ID: 35550003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions between physicians and the pharmaceutical industry: what does the literature say?
    Lexchin J
    CMAJ; 1993 Nov; 149(10):1401-7. PubMed ID: 8221424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stakeholders' views on the ethical challenges of pragmatic trials investigating pharmaceutical drugs.
    Kalkman S; van Thiel GJ; Grobbee DE; Meinecke AK; Zuidgeest MG; van Delden JJ;
    Trials; 2016 Aug; 17(1):419. PubMed ID: 27550379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perceived barriers and facilitators to Risk Based Monitoring in academic-led clinical trials: a mixed methods study.
    Hurley C; Sinnott C; Clarke M; Kearney P; Racine E; Eustace J; Shiely F
    Trials; 2017 Sep; 18(1):423. PubMed ID: 28893317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experiences with GLP/GCP from the pharmaceutical industry's viewpoint.
    Legler UF
    Methods Find Exp Clin Pharmacol; 1993 May; 15(4):233-6. PubMed ID: 8361261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GCP data quality for early clinical development.
    Rock EP; Molloy VJ; Humphrey JS
    Clin Cancer Res; 2010 Mar; 16(6):1756-63. PubMed ID: 20215550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Legal and ethical obligations to conduct a clinical drug trial in Australia as an investigator initiated and sponsored study for an overseas pharmaceutical company.
    Beran RG
    Med Law; 2004; 23(4):913-24. PubMed ID: 15685926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Barriers to clinical trials vary according to the type of trial and the institution.
    Govindarajan R; Young JW; Harless CL; Hutchins LF
    J Clin Oncol; 2007 Apr; 25(12):1633-4; author reply 1634. PubMed ID: 17443010
    [No Abstract]   [Full Text] [Related]  

  • 15. [The norms for good clinical practice in drug trials performed in Spain. A survey of the pharmaceutical industry].
    Segú JL; Lahuerta dal Ré J
    Med Clin (Barc); 1992 Jun; 99(3):106-9. PubMed ID: 1630197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [ICH-GCP Guideline: quality assurance of clinical trials. Status and perspectives].
    Englev E; Petersen KP
    Ugeskr Laeger; 2003 Apr; 165(16):1659-62. PubMed ID: 12756823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials in the Middle East and North Africa (MENA) Region: grandstanding or grandeur?
    Nair SC; Ibrahim H; Celentano DD
    Contemp Clin Trials; 2013 Nov; 36(2):704-10. PubMed ID: 23712082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A survey on the position of France in international clinical research as assessed by pharmaceutical laboratories].
    Courcier-Duplantier S; Bouhours P; Pinton P; Sibenaler C; Lassale C;
    Therapie; 2004; 59(6):629-38. PubMed ID: 15789827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barriers and Facilitating Factors for Conducting Systematic Evidence Assessments in Academic Clinical Trials.
    McLennan S; Nussbaumer-Streit B; Hemkens LG; Briel M
    JAMA Netw Open; 2021 Nov; 4(11):e2136577. PubMed ID: 34846522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current situation in clinical trials with vaccines in the Czech Republic].
    Čečetková B; Smetana J; Chlíbek R
    Epidemiol Mikrobiol Imunol; 2014 Nov; 63(4):278-84. PubMed ID: 25523220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.